CURRENT CASE STUDIES

CAR-T (Chimeric Antigen Receptor T) cell therapy is a groundbreaking immunotherapy that has shown potential in treating SLE by targeting B cells, which play a critical role in the pathogenesis of the disease. In SLE, B cells produce autoantibodies that attack the body’s tissues, leading to chronic inflammation and organ damage. CAR-T therapy works by engineering T cells to express a receptor (CAR) that specifically targets CD19, a marker on B cells, leading to the destruction of these harmful B cells.

CAR-T cells targeting CD19+ B cells provide a more effective and sustained depletion of B cells compared to other therapies like rituximab, which targets CD20 but fails to eliminate long-lived plasma cells. This profound B-cell depletion can lead to remission of SLE symptoms by eliminating the cells responsible for autoantibody production. Studies also explore CAR-Treg (CAR-T cells designed to regulate immune responses) to restore immune tolerance and reduce autoimmune activity.

FUCASO is a revolutionary BCMA-targeting CAR-T therapy by IASO BIO, offering unparalleled efficacy and safety for relapsed or refractory multiple myeloma. With high response rates, durable remission, and a robust safety profile, FUCASO provides new hope for patients and sets a new standard in CAR-T therapy.

CAR-T Therapy, short for Chimeric Antigen Receptor T-Cell Immunotherapy, is an advanced gene therapy method that involves genetically modifying a patient's own T cells to target and destroy cancer cells. Unlike traditional medications, CAR-T therapy is tailored to each patient and requires collecting T cells from the patient's blood before reinfusing them back into the body after genetic engineering.